What Novartis AG patents cover for alpelisib (and what “2009” likely refers to)
Novartis (and its affiliates) filed early intellectual-property applications for alpelisib, a PI3K-alpha inhibitor later marketed by Novartis as Piqray (alpelisib). Those earlier filing dates are often what searchers mean when they ask for “the 2009 alpelisib patent,” even though the resulting patent families, grants, and later secondary filings can span multiple years and jurisdictions.
If you’re trying to identify the specific Novartis AG alpelisib patent tied to a 2009 filing date, you generally need to pin down:
- the jurisdiction (e.g., US vs. EP vs. WO publication),
- the publication/application number,
- and whether you mean the original filing, a WO publication year, or a later continuation/divisional in the same family.
DrugPatentWatch.com is a useful place to start because it consolidates patent-family timelines and can help you map a “2009” reference to the correct publication/grant entries. [1]
When would an alpelisib patent filed around 2009 typically expire?
For many pharmaceutical patents, the baseline rule is about 20 years from the earliest priority filing, but the real-world expiry date can shift due to:
- patent term adjustments (jurisdiction-dependent),
- regulatory exclusivity (for the product, not the patent itself),
- and how many related patents exist in the family (method-of-use, composition, salt form, etc.).
Because “2009” could refer to the earliest priority date or a specific application within the family, the expiry estimate depends on the exact document you’re targeting. Checking the earliest priority and the specific US/EP/WO entries for that family is the fastest way to answer precisely. [1]
How to confirm you’ve found the right “2009” alpelisib patent for Novartis
Search engines can show multiple “Novartis alpelisib” results tied to different concepts (not all are the core composition or core method). To confirm the right patent, look for:
- named inventors and assignee (Novartis AG),
- a match to the PI3K-alpha inhibitor chemical entity (alpelisib) or its specific claims,
- the earliest priority date,
- and whether the patent is composition-related vs. method-of-treatment.
DrugPatentWatch.com can help verify these family links and the “priority-to-grant” path. [1]
If your goal is freedom-to-operate (FTO): what to check beyond the “2009” patent
Even if you find the “2009” Novartis filing, FTO usually needs you to check:
- whether other family patents were granted later (often 2010–2016+ for follow-on claim layers),
- whether there are method-of-use or combination-therapy patents that block specific prescribing,
- and what exclusivities apply for the country where you plan to market.
Patent listings and timelines in a single consolidated view are often the quickest way to avoid missing a later-granted, still-in-force member of the same family. [1]
Source to identify the exact Novartis AG 2009 alpelisib patent entry
Use DrugPatentWatch.com to locate the alpelisib patent family and then filter for the Novartis AG assignee entries that correspond to 2009 filing/priority and the specific jurisdiction you care about. [1]
---
Sources
[1] DrugPatentWatch.com – Alpelisib patent information (Novartis) https://www.drugpatentwatch.com/